TGF-P isoforms in breast cancer further highlights the methodological problems associated with determining the roles of these multifunctional peptides in both tumour progression and response to therapeutic interventions. It is important to distinguish between these two aspects of TGF-P function, and this may serve to partially reconcile some of the disparate opinions on the putative roles of TGF-P isoforms in breast cancer.
The issue of the origin of TGF-,B remains particularly controversial. As with previous studies analysing total RNA extracted from tumour samples, the data of MacCallum et al. (1994) fail to permit any distinction between epithelial and stromal sources of TGF-P mRNA. The overexpression of TGF-P in an autocrine capacity by breast epithelial cells is difficult to reconcile with its inhibitory effects upon epithelium, and the association of epithelial TGF-P1 expression with disease progression (Gorsch et al., 1992) may be a consequence of defective secretion of TGF-,B by carcinoma cells. Nonetheless, such sources of TGF-P may serve primarily to promote stromal expansion (including angiogenesis) and hence tumour growth, especially in more advanced stages of carcinogenesis. However, in the earlier and premalignant stages, TGF-P may act predominantly as an epithelial growth inhibitor via both paracrine influences from stromal cells and direct autocrine inhibition from epithelial sources of TGF-,B. In addition, TGF-P mnay inhibit endothelial proliferation in these earlier lesions (Schultz & Grant, 1991) . Though immunohistochemical studies have revealed minimal intracellular staining of stromal cells (McCune et al., 1992) , this may reflect the nuances of secretion dynamics. Moreover, whatever the role of stromal sources of TGF-P in tumour progression, they may constitute a target for stimulation of local levels of inhibitory growth factors. In a study from this laboratory (Butta et al., 1992) , we observed minimal staining of stromal cells in pretreatment samples, but intracellular staining of fibroblasts was clearly evident following tamoxifen treatment, in addition to marked up-regulation of extracellular TGF-P (between and around stromal cells). We have also recently found that primary cultures of breast tumour fibroblasts are a rich source of TGF-Pl and that levels of synthesis can be modulated by tamoxifen (our unpublished data). Such therapeutic induction of TGF-P (be it from stromal or epithelial sources) must be distinguished from growth factor status relating to neoplastic progression per se.
It is therefore necessary to investigate tumours not only at various stages of presentation, but also before and after treatment interventions. Levels of TGF-13 should be accurately localised and quantified. The authors concede that their study is purely qualitative, and that levels of TGF-,B mRNA may not accurately reflect levels of protein product owing to post-transcriptional regulation (Knabbe et al., 1987; Colletta et al., 1990 Colletta et al., , 1991 Kim et al., 1992) . However, immunohistochemical studies reveal no differences in the pattern of expression of TGF-P isoforms between benign and malignant breast tissue (Schultz & Grant, 1991) , suggesting that differential quantitative expression is functionally important. Even tiny amounts of TGF-P mRNA could yield a positive signal using the RNAse protection assay method described in this paper. Furthermore, some functional redundancy may exist within the TGF-P family, with one isoform being pre-eminent under particular circumstances.
We await with interest the results of immunohistochemical and in situ hybridisation studies. 
